Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

NCT03088267 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: amphetamine extended-release oral suspension, 2.5 mg/mL
DRUG: Placebo extended-release oral suspension

Sponsor

Tris Pharma, Inc.